Italian study tracks Real-Life results of new lung cancer combo therapy

NCT ID NCT07190677

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times

Summary

This study is collecting information from 300 people in Italy with advanced non-small cell lung cancer who are receiving a treatment that combines two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy. The goal is to see how well this treatment works in everyday medical practice, not just in controlled research settings. Researchers will track how long people live and how long their cancer stays under control, as well as any side effects they experience.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fondazione IRCCS Policlinico San Matteo
RECRUITING

Pavia, Lombardy, 27100, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER METASTATIC